Why Fresenius Medical Care Stock Might be a Great Pick

One stock that might be an intriguing choice for investors right now is Fresenius Medical Care AG FMS. This is because this security in the Medical - Instruments space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. 

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Instruments space as it currently has a Zacks Industry Rank of 66 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there. 

Meanwhile, Fresenius Medical Care is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term. 

Fresenius Medical Care AG Price and Consensus

Fresenius Medical Care AG  price-consensus-chart | Fresenius Medical Care AG Quote

In fact, over the past month, current quarter estimates have risen from 44 cents per share to 45 cents per share, while current year estimates have risen from $2.01 per share to $2.11 per share. This has helped FMS to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Fresenius Medical Care. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research